<p>In a patient with several tumours in different parts of the body, what is

Guideline-aligned answer with reasoning, red flags and references. Clinically reviewed by Dr Kola Tytler MBBS CertHE MBA MSt MRCGP.

Posted: 8 August 2026Updated: 8 August 2026 Guideline-Aligned (High Confidence) Clinically Reviewed

Most appropriate primary-care approach: treat this as malignancy of undefined primary origin (MUO)—metastatic malignancy identified on limited testing without an obvious primary—and arrange urgent specialist/MDT assessment while initiating the NICE core diagnostic screen where clinically appropriate.

1. Clarify the presentation and urgency. Take a comprehensive cancer-focused history and perform full examination, including breast, nodal areas, skin, genital, rectal and pelvic examination, to identify a likely primary and to distinguish metastatic carcinoma from potentially treatable non-epithelial malignancies such as lymphoma, melanoma, sarcoma, germ-cell or other haematological malignancy.

Assess performance status, symptoms needing urgent intervention, and whether the patient is fit for and willing to consider treatment, because investigations should be undertaken only when results are likely to alter a treatment decision and the patient understands and accepts their potential benefits and risks.

Where progressive subacute loss of central neurological function suggests brain or CNS cancer, arrange urgent direct-access brain MRI, or CT if MRI is contraindicated, to be performed within 2 weeks.

2. Undertake the initial MUO investigation set, guided by symptoms. Request FBC, U&Es/creatinine, LFTs, corrected calcium, urinalysis and LDH.

Arrange chest X-ray and CT of chest, abdomen and pelvis to define disease distribution, identify a possible primary, select an accessible biopsy target and provide the initial anatomical assessment of extent.

Request a myeloma screen if there are isolated or multiple lytic bone lesions.

Use symptom-directed endoscopy rather than routine pan-endoscopy; upper or lower GI endoscopy should be performed only when symptoms, histology or imaging suggest a gastrointestinal primary.

3. Use targeted rather than broad tumour-marker testing. Do not send indiscriminate tumour markers, as NICE restricts their diagnostic use because of limited specificity.

Use PSA in men with a presentation compatible with prostate cancer, CA125 in women with peritoneal malignancy or ascites compatible with ovarian cancer, AFP and hCG for suspected germ-cell tumour—particularly a mediastinal or retroperitoneal mass in a young man—and AFP when hepatocellular cancer is suspected.

Arrange testicular ultrasound in men whose presentation is compatible with a germ-cell tumour.

4. Obtain tissue safely and establish tumour lineage. Arrange biopsy of the safest, most informative accessible lesion, with standard histology and immunohistochemistry as necessary, to distinguish carcinoma from lymphoma, melanoma, sarcoma, germ-cell tumour and other malignant diagnoses.

Obtain a histological tissue sample in malignant ascites when technically possible.

Avoid inappropriate biopsy of a lesion that might represent a resectable primary or oligometastatic disease, because biopsy of a primary bone tumour can compromise surgical options and percutaneous biopsy of a potentially resectable liver metastasis may compromise outcome.

For adenocarcinoma of unknown origin, specialist pathology should use CK7, CK20, TTF-1, PLAP, ER in women and PSA in men, followed by additional immunohistochemistry directed by these results and the clinical picture.

5. Refer early for coordinated primary-site assignment and staging. The diagnostic aim is to identify a primary site that directs treatment, identify a non-epithelial malignancy that may be treated irrespective of primary site, or classify metastatic epithelial/neuroendocrine malignancy with no detected primary as provisional CUP.

After the selected initial screen and tissue diagnosis, refer to the relevant site-specific MDT or CUP team/network MDT for interpretation of imaging and pathology, planning of any further targeted investigations, and formal cancer-specific staging.

If no primary is found after specialist review and appropriate further specialised investigations, the diagnosis becomes confirmed CUP.

Consider FDG PET-CT only in specialist-directed circumstances: offer it for provisional CUP with cervical lymphadenopathy after negative ENT panendoscopy when radical treatment is an option, and consider it for extra-cervical presentations after discussion with the CUP team or network MDT.

Do not routinely arrange mammography in women with MUO unless clinical or pathological features suggest breast cancer; adenocarcinoma in axillary nodes warrants referral to a breast MDT, with contrast-enhanced breast MRI considered after negative standard breast assessment to locate a biopsy target.

6. Establish stage through the responsible oncology MDT. CT chest/abdomen/pelvis provides the initial map of metastatic burden, but definitive staging uses the confirmed histology, primary site when found, tumour extent, nodal involvement and distant metastases within the relevant site-specific staging system. ,

Document prognostic factors that influence both investigation and treatment decisions, particularly performance status, liver metastases, LDH and serum albumin.

In a patient unfit for treatment, do not pursue further investigations solely to identify the primary site; explain when further testing will not change treatment options and ensure supportive and palliative care needs are addressed.

Related Knowledge Topics

Educational content only. Always verify information and use clinical judgement.